- Home
- ALNY vs CCEP Comparison
ALNY vs CCEP Comparison
Compare ALNY & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- CCEP
- Stock Information
- Founded
- ALNY 2002
- CCEP 1986
- Country
- ALNY United States
- CCEP United Kingdom
- Employees
- ALNY N/A
- CCEP N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- CCEP Beverages (Production/Distribution)
- Sector
- ALNY Health Care
- CCEP Consumer Staples
- Exchange
- ALNY Nasdaq
- CCEP Nasdaq
- Market Cap
- ALNY 33.2B
- CCEP 35.5B
- IPO Year
- ALNY 2004
- CCEP 1987
- Fundamental
- Price
- ALNY $264.99
- CCEP $77.64
- Analyst Decision
- ALNY Buy
- CCEP Strong Buy
- Analyst Count
- ALNY 24
- CCEP 8
- Target Price
- ALNY $299.09
- CCEP $84.86
- AVG Volume (30 Days)
- ALNY 643.5K
- CCEP 1.5M
- Earning Date
- ALNY 02-13-2025
- CCEP 02-21-2025
- Dividend Yield
- ALNY N/A
- CCEP 2.75%
- EPS Growth
- ALNY N/A
- CCEP N/A
- EPS
- ALNY N/A
- CCEP 3.75
- Revenue
- ALNY $2,094,795,000.00
- CCEP $20,521,804,348.00
- Revenue This Year
- ALNY $24.87
- CCEP $14.83
- Revenue Next Year
- ALNY $18.53
- CCEP $4.74
- P/E Ratio
- ALNY N/A
- CCEP $20.82
- Revenue Growth
- ALNY 21.54
- CCEP 6.31
- 52 Week Low
- ALNY $141.98
- CCEP $65.77
- 52 Week High
- ALNY $304.39
- CCEP $82.32
- Technical
- Relative Strength Index (RSI)
- ALNY 61.89
- CCEP 58.01
- Support Level
- ALNY $245.69
- CCEP $74.84
- Resistance Level
- ALNY $256.93
- CCEP $76.25
- Average True Range (ATR)
- ALNY 9.38
- CCEP 1.31
- MACD
- ALNY 2.95
- CCEP 0.24
- Stochastic Oscillator
- ALNY 99.91
- CCEP 81.70
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About CCEP Coca-Cola Europacific Partners plc
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe (80% of 2023 revenue and EBIT) and Australasia (20%).In 2023, CCEP sold 3.3 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume. Coke's largest bottler, Coca-Cola Femsa sold 4 billion unit cases (12%), and the third-largest, Coca-Cola HBC, serving Eastern Europe and North Africa, sold 2.8 billion unit cases (8%).TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.